Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Robert Schooley

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0711
    CA La Jolla 92093
    Phone858-822-0216
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Enhancing Advanced Biomedical Training in Mozambique
      NIH/FIC D43TW010568Jun 12, 2017 - May 31, 2022
      Role: Principal Investigator
      Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
      NIH/NIAID R01AI131424Feb 21, 2017 - Jan 31, 2022
      Role: Principal Investigator
      Orally Active Nucleoside Phosphonates for Hepatitis C Virus
      NIH/NIAID R01AI076558Apr 1, 2009 - Mar 31, 2014
      Role: Principal Investigator
      Multiplex Nucleic Acid Detection Devices for the Diagnosis of Respiratory Viruses
      NIH/NIAID U01AI074521Jul 1, 2007 - Dec 31, 2012
      Role: Principal Investigator
      Rocky Mountain Regional Center of Excellence or Biodefense and Emerging Infectiou
      NIH U54AI065357Jun 1, 2005 - Apr 30, 2014
      Role: Co-Investigator
      Immunopathogenesis of Acute HIV-1 Infection
      NIH/NIAID P01AI055356Sep 30, 2003 - Mar 31, 2010
      Role: Principal Investigator
      U of Colorado Center for AIDS Research
      NIH/NIAID P30AI054907May 15, 2003 - Apr 30, 2010
      Role: Principal Investigator
      IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION
      NIH/NIAID U01AI041536Jul 1, 1997 - Jun 30, 2005
      Role: Principal Investigator
      ADULT ACTG CENTRAL GROUP
      NIH/NIAID U01AI038858Jan 1, 1996 - Dec 31, 2008
      Role: Principal Investigator
      CONFERENCE ON IMMUNOPATHOGENESIS OF HIV INFECTION
      NIH/NIAID R13AI039810Jan 1, 1996 - Dec 31, 1996
      Role: Principal Investigator
      Center for AIDS Research
      NIH/NIAID P30AI036214Apr 1, 1994 - Mar 31, 2018
      Role: Co-Investigator
      DESIGN OF BIOLOGICALLY ACTIVE ANTI-HIV-1 RIBOZYMES
      NIH/NIAID U01AI035226Jan 1, 1994 - Dec 31, 1996
      Role: Principal Investigator
      Colorado HIV Research Training Program
      NIH/NIAID T32AI007447Sep 30, 1992 - Aug 31, 2017
      Role: Principal Investigator
      COLORADO ADULT AIDS CLINICAL TRIALS UNIT
      NIH/NIAID U01AI032770Mar 1, 1992 - Dec 31, 2006
      Role: Principal Investigator
      AIDS &RELATED RESEARCH 1 STUDY SECTION
      NIH/CSR U09RG000131Jul 1, 1990 - Jan 31, 1991
      Role: Principal Investigator
      CELL MEDIATED IMMUNE RESPONSE TO HUMAN RETROVIRUSES
      NIH/NCI R01CA037461Apr 1, 1984 - Aug 31, 1996
      Role: Principal Investigator
      HUMAN T-CELL LEUKEMIA VIRUS--VIRUS-HOST INTERACTIONS
      NIH/NCI U01CA037461Apr 1, 1984 - Mar 31, 1987
      Role: Principal Investigator
      General Clinical Research Center
      NIH M01RR000051Dec 1, 1978 - Mar 31, 2010
      Role: Co-Investigator
      Research in Infectious Disease
      NIH/NIAID T32AI007036Jul 1, 1976 - Jun 30, 2021
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley R, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151. PMID: 28208122.
        View in: PubMed
      2. Schooley R, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017 Aug 14. PMID: 28807909.
        View in: PubMed
      3. Virgínia Noormahomed E, Carrilho C, Ismail M, Noormahomed S, Nguenha A, Benson CA, Mocumbi AO, Schooley R. The Medical Education Partnership Initiative (MEPI), a collaborative paradigm for institutional and human resources capacity building between high- and low- and middle-income countries: the Mozambique experience. Glob Health Action. 2017; 10(1):1272879. PMID: 28452653.
        View in: PubMed
      4. Schooley R, Fang FC. Skating to Where the Puck Is Going to Be. Clin Infect Dis. 2017 Jan 01; 64(1):1-2. PMID: 27986765.
        View in: PubMed
      5. Logan C, Todorof K, Fiorillo SP, Campbell TB, Elder JH, Borok M, Gudza I, Gwanzura L, Ndemera B, Lochhead MJ, Benson CA, Schooley R. Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus. PLoS One. 2016; 11(9):e0163616. PMID: 27669509.
        View in: PubMed
      6. Chen HW, Liu PF, Liu YT, Kuo S, Zhang XQ, Schooley R, Rohde H, Gallo RL, Huang CM. Nasal commensal Staphylococcus epidermidis counteracts influenza virus. Sci Rep. 2016; 6:27870. PMID: 27306590.
        View in: PubMed
      7. Cachay ER, Wyles D, Hill L, Ballard C, Torriani F, Colwell B, Kuo A, Schooley R, Mathews CW. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care. Open Forum Infect Dis. 2015 Dec; 2(4):ofv168. PMID: 26697509.
        View in: PubMed
      8. Carlin AF, Aristizabal P, Song Q, Wang H, Paulson MS, Stamm LM, Schooley R, Wyles DL. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology. 2015 Oct; 62(4):1047-58. PMID: 26147061.
        View in: PubMed
      9. Schooley R. Reply to Christopher and Kortepeter. Clin Infect Dis. 2015 Nov 1; 61(9):1489-90. PMID: 26175523.
        View in: PubMed
      10. Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley R. Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population. PLoS One. 2015; 10(6):e0129519. PMID: 26053030.
        View in: PubMed
      11. Givens M, Weaver A, Bickman S, Logan C, Noormahomed EV, Patel S, Schooley R, Benson CA, Lochhead MJ. Near patient CD4 count in a hospitalized HIV patient population. Cytometry B Clin Cytom. 2015 Apr 27. PMID: 25917935.
        View in: PubMed
      12. Schooley R. Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War? Clin Infect Dis. 2015 Aug 15; 61(4):503-5. PMID: 25904373.
        View in: PubMed
      13. Preziosi M, Zimba TF, Lee K, Tomas M, Kinlin S, Nhatave-Paiva C, Bene R, Paunde T, Lopes H, Kalkhoff S, Prathap V, Akrami K, Noormahomed EV, Schooley R, Aronoff-Spencer E. A prospective observational study of bacteraemia in adults admitted to an urban Mozambican hospital. S Afr Med J. 2015 May; 105(5):7402. PMID: 26242671.
        View in: PubMed
      14. Huang ML, Cohen M, Fisher CJ, Schooley R, Gagneux P, Godula K. Determination of receptor specificities for whole influenza viruses using multivalent glycan arrays. Chem Commun (Camb). 2015 Mar 12; 51(25):5326-9. PMID: 25574528.
        View in: PubMed
      15. Gois L, Badaró R, Schooley R, Grassi MF. Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report. BMC Infect Dis. 2015; 15(1):38. PMID: 25645330.
        View in: PubMed
      16. Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, Wrin T, Schooley R, Lederman MM, Kuritzkes DR. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS. 2014 Nov 28; 28(18):2649-57. PMID: 25254301.
        View in: PubMed
      17. Gutierrez JA, Jones KA, Flores R, Singhania A, Woelk CH, Schooley R, Wyles DL. Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression. J Virol Antivir Res. 2014 Oct 6; 3(3). PMID: 26594646.
        View in: PubMed
      18. Mocumbi AO, Carrilho C, Aronoff-Spencer E, Funzamo C, Patel S, Preziosi M, Lederer P, Tilghman W, Benson CA, Badaró R, Nguenha A, Schooley R, Noormahomed EV. Innovative strategies for transforming internal medicine residency training in resource-limited settings: the mozambique experience. Acad Med. 2014 Aug; 89(8 Suppl):S78-82. PMID: 25072585.
        View in: PubMed
      19. Lin JC, Habersetzer F, Rodriguez-Torres M, Afdhal N, Lawitz EJ, Paulson MS, Zhu Y, Subramanian GM, McHutchison JG, Sulkowski M, Wyles DL, Schooley R. Interferon ?-Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response. J Infect Dis. 2014 Dec 15; 210(12):1881-5. PMID: 24907384.
        View in: PubMed
      20. Orlov M, Vaida F, Williamson K, Deng Q, Smith DM, Duffy PE, Schooley R. Antigen-Presenting Phagocytic Cells Ingest Malaria Parasites and Increase HIV Replication in a Tumor Necrosis Factor a-Dependent Manner. J Infect Dis. 2014 Nov 15; 210(10):1562-72. PMID: 24903666.
        View in: PubMed
      21. Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley R, Gwanzura L, Borok M, Campbell TB. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. Int J Infect Dis. 2014 Jul; 24:6-10. PMID: 24769175.
        View in: PubMed
      22. Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley R, Hughes MD, Coffin JM, Mellors JW. Low-Frequency Nevirapine (NVP)-Resistant HIV-1 Variants Are Not Associated With Failure of Antiretroviral Therapy in Women Without Prior Exposure to Single-Dose NVP. J Infect Dis. 2014 Mar; 209(5):703-10. PMID: 24443547.
        View in: PubMed
      23. Noormahomed EV, Mocumbi AO, Preziosi M, Damasceno A, Bickler S, Smith DM, Funzamo C, Aronoff-Spencer E, Badaró R, Mabila F, Bila D, Nguenha A, Do Rosário V, Benson CA, Schooley R, Patel S, Ferrão LJ, Carrilho C. Strengthening research capacity through the medical education partnership initiative: the Mozambique experience. Hum Resour Health. 2013; 11(1):62. PMID: 24304706.
        View in: PubMed
      24. Schooley R. The fragile relationship between hepatitis C virus and its human host. Top Antivir Med. 2013 Dec; 21(5):148-51. PMID: 24531554.
        View in: PubMed
      25. Cohen M, Zhang XQ, Senaati HP, Chen HW, Varki NM, Schooley R, Gagneux P. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J. 2013; 10:321. PMID: 24261589.
        View in: PubMed
      26. Afdhal NH, Zeuzem S, Schooley R, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat. 2013 Nov; 20(11):745-60. PMID: 24168254.
        View in: PubMed
      27. Mistro S, Schooley R, Badaro R. Reply to messori et Al. Clin Infect Dis. 2013 Dec; 57(12):1784-5. PMID: 24140973.
        View in: PubMed
      28. Gois LL, Mehta S, Rodrigues MZ, Schooley R, Badaró R, Grassi MF. Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis. Mem Inst Oswaldo Cruz. 2013 Oct 2; 109(1):9-14. PMID: 24141962.
        View in: PubMed
      29. Chen HW, Cheng JX, Liu MT, King K, Peng JY, Zhang XQ, Wang CH, Shresta S, Schooley R, Liu YT. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses. Antiviral Res. 2013 Sep; 99(3):371-82. PMID: 23820269.
        View in: PubMed
      30. Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, Poongulali S, Kumarasamy N, Schooley R, Solomon S, Kantor R. Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):630-2. PMID: 23045961.
        View in: PubMed
      31. Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley R, Benson CA. Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol Methods. 2013 Jan 31; 387(1-2):107-13. PMID: 23063690.
        View in: PubMed
      32. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley R, De Gruttola V, Hakim JG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012; 9(8):e1001290. PMID: 22936892.
        View in: PubMed
      33. Noormahomed EV, Orlov M, do Rosario V, Petersen BW, Guthrie C, Badaro R, Schooley R. A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa. Malar J. 2012; 11:252. PMID: 22853699.
        View in: PubMed
      34. Orlov M, Vaida F, Finney OC, Smith DM, Talley AK, Wang R, Kappe SH, Deng Q, Schooley R, Duffy PE. P. falciparum enhances HIV replication in an experimental malaria challenge system. PLoS One. 2012; 7(6):e39000. PMID: 22745697.
        View in: PubMed
      35. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012; 9(6):e1001236. PMID: 22719231.
        View in: PubMed
      36. Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley R, Walensky RP. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012 Jun 1; 26(9):1083-93. PMID: 22343964.
        View in: PubMed
      37. Saravanan S, Madhavan V, Kantor R, Sivamalar S, Gomathi S, Solomon SS, Kumarasamy N, Smith DM, Schooley R, Solomon S, Balakrishnan P. Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1763-5. PMID: 22404052.
        View in: PubMed
      38. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley R, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012 Jun; 54(12):1774-7. PMID: 22491505.
        View in: PubMed
      39. Schooley R. Hepatitis C virus therapeutics: at the end of the beginning. Top Antivir Med. 2012 Apr-May; 20(1):17-9. PMID: 22538246.
        View in: PubMed
      40. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley R, Kuritzkes DR. Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012; 7(3):e34134. PMID: 22479542.
        View in: PubMed
      41. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley R, Wyles DL. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012 Feb 15; 205(4):656-62. PMID: 22279172.
        View in: PubMed
      42. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley R, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012; 7(1):e30306. PMID: 22291932.
        View in: PubMed
      43. Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, Rowley K, Vogel K, Myatt C, Zhang XQ, Logan C, Benson C, Reed S, Schooley R. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol. 2011 Oct; 49(10):3584-90. PMID: 21865431.
        View in: PubMed
      44. Rodrigues MZ, Grassi MF, Mehta S, Zhang XQ, Gois LL, Schooley R, Badaro R. Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil. Clin Vaccine Immunol. 2011 Oct; 18(10):1765-9. PMID: 21832098.
        View in: PubMed
      45. Valiaeva N, Wyles DL, Schooley R, Hwu JB, Beadle JR, Prichard MN, Hostetler KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem. 2011 Aug 1; 19(15):4616-25. PMID: 21719300.
        View in: PubMed
      46. Holmes EC, Ghedin E, Halpin RA, Stockwell TB, Zhang XQ, Fleming R, Davey R, Benson CA, Mehta S, Taplitz R, Liu YT, Brouwer KC, Wentworth DE, Lin X, Schooley R. Extensive geographical mixing of 2009 human H1N1 influenza A virus in a single university community. J Virol. 2011 Jul; 85(14):6923-9. PMID: 21593168.
        View in: PubMed
      47. DeGruttola V, Schooley R. Antiretroviral therapy as prevention: linking the mainframe to Main Street. Clin Infect Dis. 2011 Apr 15; 52(8):1050-2. PMID: 21460323.
        View in: PubMed
      48. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington M, Walker BD, Schooley R, Kuritzkes DR. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis. 2011 Apr 1; 203(7):976-83. PMID: 21402549.
        View in: PubMed
      49. Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley R, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology. 2011 Mar; 140(3):755-60. PMID: 21255574.
        View in: PubMed
      50. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011 Feb 15; 203(4):442-51. PMID: 21245157.
        View in: PubMed
      51. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley R, Currier JS. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509. PMID: 20942666.
        View in: PubMed
      52. Schooley R, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010 Sep 1; 202(5):705-16. PMID: 20662716.
        View in: PubMed
      53. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Gwanzura L, Schooley R, Campbell TB. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis. 2010 Aug 1; 51(3):342-9. PMID: 20572760.
        View in: PubMed
      54. Rodwell TC, Robertson AM, Aguirre N, Vera A, Anderson CM, Lozada R, Chait L, Schooley R, Zhang XQ, Strathdee SA. Pandemic (H1N1) 2009 Surveillance in Marginalized Populations, Tijuana, Mexico. Emerg Infect Dis. 2010 Aug; 16(8):1292-5. PMID: 20678328.
        View in: PubMed
      55. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley R. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21; 304(3):321-33. PMID: 20639566.
        View in: PubMed
      56. Mehta SR, Zhang XQ, Badaro R, Spina C, Day J, Chang KP, Schooley R. Flow cytometric screening for anti-leishmanials in a human macrophage cell line. Exp Parasitol. 2010 Dec; 126(4):617-20. PMID: 20540940.
        View in: PubMed
      57. Chen CH, Zhang XQ, Lo CW, Liu PF, Liu YT, Gallo RL, Hsieh MF, Schooley R, Huang CM. The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus. Proteomics. 2010 Jun; 10(12):2396-401. PMID: 20391540.
        View in: PubMed
      58. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley R, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010 Jun 1; 201(11):1686-96. PMID: 20420510.
        View in: PubMed
      59. Wyles DL, Schooley R. Rong's numbers: accelerating progress in HCV therapeutic research. Sci Transl Med. 2010 May 26; 2(33):33ps25. PMID: 20505213.
        View in: PubMed
      60. Monto A, Schooley R, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol. 2010 May; 105(5):989-1004; quiz 988, 1005. PMID: 20087331.
        View in: PubMed
      61. Lu Q, Zhang XQ, Pond SL, Reed S, Schooley R, Liu YT. Detection in 2009 of the swine origin influenza A (H1N1) virus by a subtyping microarray. J Clin Microbiol. 2009 Sep; 47(9):3060-1. PMID: 19605579.
        View in: PubMed
      62. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, Mayer KH, Benson C, Schooley R. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009 Jul 15; 49(2):306-9. PMID: 19522657.
        View in: PubMed
      63. Wyles DL, Kaihara KA, Korba BE, Schooley R, Beadle JR, Hostetler KY. The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother. 2009 Jun; 53(6):2660-2. PMID: 19289518.
        View in: PubMed
      64. DeGruttola V, Little S, Schooley R. Controlling the HIV epidemic, without a vaccine! AIDS. 2008 Nov 30; 22(18):2554-5. PMID: 19005285.
        View in: PubMed
      65. Mehta SR, Huang R, Yang M, Zhang XQ, Kolli B, Chang KP, Hoffman RM, Goto Y, Badaro R, Schooley R. Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clin Vaccine Immunol. 2008 Dec; 15(12):1764-70. PMID: 18945882.
        View in: PubMed
      66. Hammer SM, Eron JJ, Reiss P, Schooley R, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008 Aug 6; 300(5):555-70. PMID: 18677028.
        View in: PubMed
      67. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley R, Springer MS, Veazey RS, Wainberg MA. Whither or wither microbicides? Science. 2008 Jul 25; 321(5888):532-4. PMID: 18653884.
        View in: PubMed
      68. Smith DM, Schooley R. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis. 2008 May 15; 46(10):1598-600. PMID: 18419496.
        View in: PubMed
      69. Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley R, Benson CA. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol. 2008 Jun; 15(6):986-94. PMID: 18400976.
        View in: PubMed
      70. Wyles DL, Kaihara KA, Schooley R. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob Agents Chemother. 2008 May; 52(5):1862-4. PMID: 18332167.
        View in: PubMed
      71. Grünberger C, Wyles DL, Kaihara KA, Schooley R. 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis. 2008 Jan 1; 197(1):42-5. PMID: 18171283.
        View in: PubMed
      72. Al-Harthi L, MaWhinney S, Connick E, Schooley R, Forster JE, Benson C, Thompson M, Judson F, Palella F, Landay A. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007 Dec; 125(3):299-308. PMID: 17916441.
        View in: PubMed
      73. Schooley R, Mellors JW. No cure yet for HIV-1, but therapeutic research presses on. J Infect Dis. 2007 Mar 15; 195(6):770-2. PMID: 17299705.
        View in: PubMed
      74. Sailer CA, Pott GB, Dinarello CA, Whinney SM, Forster JE, Larson-Duran JK, Landay A, Al-Harthi L, Schooley R, Benson CA, Judson FN, Thompson M, Palella FJ, Shapiro L. Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis. 2007 Mar 1; 195(5):734-8. PMID: 17262717.
        View in: PubMed
      75. Wyles DL, Kaihara KA, Vaida F, Schooley R. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007 Mar; 81(6):3005-8. PMID: 17182685.
        View in: PubMed
      76. Garcia R, Badaró R, Netto EM, Silva M, Amorin FS, Ramos A, Vaida F, Brites C, Schooley R. Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1248-52. PMID: 17209767.
        View in: PubMed
      77. Schooley R. Viral load testing in resource-limited settings. Clin Infect Dis. 2007 Jan 1; 44(1):139-40. PMID: 17143830.
        View in: PubMed
      78. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley R, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5. PMID: 17062652.
        View in: PubMed
      79. Frey G, Rits-Volloch S, Zhang XQ, Schooley R, Chen B, Harrison SC. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):13938-43. PMID: 16963566.
        View in: PubMed
      80. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley R, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006 Aug 16; 296(7):827-43. PMID: 16905788.
        View in: PubMed
      81. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley R, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006 Aug-Sep; 14(3):827-43. PMID: 17016878.
        View in: PubMed
      82. Zhang XQ, Sorensen M, Fung M, Schooley R. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother. 2006 Jun; 50(6):2231-3. PMID: 16723592.
        View in: PubMed
      83. Schooley R. HIV and hepatitis C virus coinfection: bad bedfellows. Top HIV Med. 2005 Oct-Nov; 13(4):112-6. PMID: 16304454.
        View in: PubMed
      84. Neid JM, Schooley R, Campbell TB. Stimulation of Kaposi's sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim. Am J Hematol. 2004 Dec; 77(4):410-2. PMID: 15551282.
        View in: PubMed
      85. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley R, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 Jul 14; 292(2):251-65. PMID: 15249575.
        View in: PubMed
      86. Campbell TB, Rapaport E, Schooley R, Kuritzkes DR. Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis. 2004 Jul 15; 190(2):257-66. PMID: 15216459.
        View in: PubMed
      87. Garcia R, Schooley R, Badaró R. An adherence trilogy is essential for long-term HAART success. Braz J Infect Dis. 2003 Oct; 7(5):307-14. PMID: 14552740.
        View in: PubMed
      88. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley R, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002 Jul 10; 288(2):222-35. PMID: 12095387.
        View in: PubMed
      89. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley R, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002 Jun 14; 16(9):1227-35. PMID: 12045487.
        View in: PubMed
      90. Schooley R, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002 Jun 14; 16(9):1257-63. PMID: 12045491.
        View in: PubMed
      91. Connick E, Schlichtemeier RL, Purner MB, Schneider KM, Anderson DM, MaWhinney S, Campbell TB, Kuritzkes DR, Douglas JM, Judson FN, Schooley R. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis. 2001 Dec 1; 184(11):1465-9. PMID: 11709791.
        View in: PubMed
      92. Schooley R, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME, Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Antivir Ther. 2001 Jun; 6(2):89-96. PMID: 11491421.
        View in: PubMed
      93. Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Schooley R, Richman D, Corey L, Haase AT. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis. 2001 Feb 15; 183(4):555-62. PMID: 11170980.
        View in: PubMed
      94. Schooley R, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov; 182(5):1357-64. PMID: 11023459.
        View in: PubMed
      95. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L, Schooley R. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS. 2000 Sep 29; 14(14):2109-16. PMID: 11061651.
        View in: PubMed
      96. Fahey JL, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey JL, Seigel J, Landay AL, Kilarui R, Schmitz JL, White C, Wara DW, Akridge R, Cutili J, Douglas SD, Reuben J, Shearer WT, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, Waxdal M. Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation. Clin Diagn Lab Immunol. 2000 Jul; 7(4):540-8. PMID: 10882648.
        View in: PubMed
      97. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley R, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000 Jan 19; 283(3):381-90. PMID: 10647802.
        View in: PubMed
      98. Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, Mladenovic J, Landay A, Wong R, Ambruso D, Miles S, Pomerantz RJ, Schooley R. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 1; 95(1):48-55. PMID: 10607683.
        View in: PubMed
      99. Schooley R, Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz RJ, Campbell TB, Bell D, Ambruso D, Wong R, Landay A, Coombs RW, Fox L, Kamoun M, Jacovini J. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57. PMID: 10608761.
        View in: PubMed
      100. Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS. 1999 Dec 3; 13(17):2411-20. PMID: 10597783.
        View in: PubMed
      101. Zhang XQ, Schooley R, Gerber JG. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999 Dec; 180(6):1833-7. PMID: 10558938.
        View in: PubMed
      102. Campbell TB, Fitzpatrick L, MaWhinney S, Zhang X, Schooley R. Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection. J Acquir Immune Defic Syndr. 1999 Dec 1; 22(4):333-40. PMID: 10634194.
        View in: PubMed
      103. Schooley R. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis. 1999 Jul; 29(1):12-8. PMID: 10433560.
        View in: PubMed
      104. Saag MS, Sonnerborg A, Torres RA, Lancaster D, Gazzard BG, Schooley R, Romero C, Kelleher D, Spreen W, LaFon S. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS. 1998 Nov 12; 12(16):F203-9. PMID: 9833848.
        View in: PubMed
      105. Zhang Xq, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo Md, Brites C, Pedral-Sampaio D, Schooley R. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis. 1998 Nov; 178(5):1488-91. PMID: 9780272.
        View in: PubMed
      106. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley R. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS. 1998 Oct 1; 12(14):1823-32. PMID: 9792383.
        View in: PubMed
      107. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley R, Thompson MA, Torres RA, Tsoukas CM. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS. 1998 Jul 30; 12(11):F103-9. PMID: 9708399.
        View in: PubMed
      108. McFarland EJ, Harding PA, MaWhinney S, Schooley R, Kuritzkes DR. In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. J Immunol. 1998 Jul 1; 161(1):513-9. PMID: 9647263.
        View in: PubMed
      109. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley R, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998 Jul 1; 280(1):78-86. PMID: 9660368.
        View in: PubMed
      110. Saag MS, Schooley R. Antiretroviral chemotherapy. Curr Clin Top Infect Dis. 1998; 18:154-79. PMID: 9779354.
        View in: PubMed
      111. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley R, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25; 277(24):1962-9. PMID: 9200638.
        View in: PubMed
      112. Cotton D, Bartlett J, Schooley R, Gulick R. Therapeutic decision making in 1997. Roundtable discussion of five cases. AIDS Clin Care. 1997 Feb; 9(2):11-5, 18. PMID: 12212541.
        View in: PubMed
      113. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley R, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10; 335(15):1081-90. PMID: 8813038.
        View in: PubMed
      114. Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley R, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep; 70(9):5922-9. PMID: 8709213.
        View in: PubMed
      115. Uherova P, Connick E, MaWhinney S, Schlichtemeier R, Schooley R, Kuritzkes DR. In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. J Infect Dis. 1996 Sep; 174(3):483-9. PMID: 8769604.
        View in: PubMed
      116. Connick E, Marr DG, Zhang XQ, Clark SJ, Saag MS, Schooley R, Curiel TJ. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses. 1996 Aug 10; 12(12):1129-40. PMID: 8844017.
        View in: PubMed
      117. Schooley R, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1; 12(4):363-70. PMID: 8673545.
        View in: PubMed
      118. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Sáag MS, Schooley R, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10; 276(2):146-54. PMID: 8656507.
        View in: PubMed
      119. Schooley R, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis. 1996 Jun; 173(6):1354-66. PMID: 8648207.
        View in: PubMed
      120. Benson EM, French MA, Schooley R. Managing HIV. Part 4: Primary therapy. 4.2 Immune-based therapy for HIV infection. Med J Aust. 1996 Mar 4; 164(5):297-300. PMID: 8628166.
        View in: PubMed
      121. Schooley R. Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Adv Exp Med Biol. 1996; 394:405-10. PMID: 8815705.
        View in: PubMed
      122. Schooley R. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS. 1995 Dec; 9 Suppl 2:S15-S19. PMID: 8775802.
        View in: PubMed
      123. Hibberd PL, Surman OS, Bass M, Tolkoff-Rubin NE, Cosimi AB, Schooley R, Doran M, Delvecchio A, Rosal M, Rubin R. Psychiatric disease and cytomegalovirus viremia in renal transplant recipients. Psychosomatics. 1995 Nov-Dec; 36(6):561-3. PMID: 7501787.
        View in: PubMed
      124. Schooley R. Immunomodulatory effects of antiretroviral chemotherapy. J Biol Regul Homeost Agents. 1995 Jul-Sep; 9(3):110-3. PMID: 8782019.
        View in: PubMed
      125. Schooley R. HIV-1-specific cytotoxic T-cell responses. AIDS. 1995; 9 Suppl A:S113-6. PMID: 8819578.
        View in: PubMed
      126. Choi S, Lagakos SW, Schooley R, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993 May 1; 118(9):674-80. PMID: 8096373.
        View in: PubMed
      127. McFarland EJ, Curiel TJ, Schoen DJ, Rosandich ME, Schooley R, Kuritzkes DR. Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child. J Infect Dis. 1993 Mar; 167(3):719-23. PMID: 7680062.
        View in: PubMed
      128. Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley R, Daar ES. Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med. 1993 Feb 11; 328(6):380-5. PMID: 8093634.
        View in: PubMed
      129. Yeni P, Schooley R, Hammer S. Antiretroviral and immune-based therapies: update. AIDS. 1993; 7 Suppl 1:S173-84. PMID: 8363782.
        View in: PubMed
      130. Curiel TJ, Wong JT, Gorczyca PF, Schooley R, Walker BD. CD4+ human immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1-infected individual. AIDS Res Hum Retroviruses. 1993 Jan; 9(1):61-8. PMID: 7678973.
        View in: PubMed
      131. Zhang XQ, Yang L, Ho DD, Kuritzkes DR, Chen IS, Ching WT, Chen YM, Schooley R. Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. J Infect Dis. 1992 May; 165(5):805-12. PMID: 1373751.
        View in: PubMed
      132. Fahey JL, Schooley R. Status of immune-based therapies in HIV infection and AIDS. Clin Exp Immunol. 1992 Apr; 88(1):1-5. PMID: 1563093.
        View in: PubMed
      133. Schooley R. Challenges in the clinical development of antiretroviral drugs. Antiviral Res. 1992 Apr; 17(4):305-10. PMID: 1642481.
        View in: PubMed
      134. Conway B, Baskar P, Bechtel LJ, Kaplan JC, Hirsch MS, Schooley R, Pincus SH. Eosinophils as host cells for HIV-1. Arch Virol. 1992; 127(1-4):373-7. PMID: 1456897.
        View in: PubMed
      135. Chen YM, Zhang XQ, Dahl CE, Samuel KP, Schooley R, Essex M, Papas TS. Delineation of type-specific regions on the envelope glycoproteins of human T cell leukemia viruses. J Immunol. 1991 Oct 1; 147(7):2368-76. PMID: 1717557.
        View in: PubMed
      136. Conway B, Tomford W, Mankin HJ, Hirsch MS, Schooley R. Radiosensitivity of HIV-1--potential application to sterilization of bone allografts. AIDS. 1991 May; 5(5):608-9. PMID: 1863419.
        View in: PubMed
      137. Goldfeld AE, Birch-Limberger K, Schooley R, Walker BD. HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription. J Acquir Immune Defic Syndr. 1991; 4(1):41-7. PMID: 1845771.
        View in: PubMed
      138. Schooley R. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis. 1990 Sep-Oct; 12 Suppl 7:S811-9. PMID: 2173110.
        View in: PubMed
      139. Schooley R, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med. 1990 Feb 15; 112(4):247-53. PMID: 2297203.
        View in: PubMed
      140. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, Schooley R. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989 Dec; 86(23):9514-8. PMID: 2480604.
        View in: PubMed
      141. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley R. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989 Nov 3; 262(17):2405-10. PMID: 2677429.
        View in: PubMed
      142. Johnson VA, Barlow MA, Chou TC, Fisher RA, Walker BD, Hirsch MS, Schooley R. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Infect Dis. 1989 May; 159(5):837-44. PMID: 2785146.
        View in: PubMed
      143. Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischl M, Schooley R, Hirsch M, Soo W, Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med. 1989 Feb 1; 110(3):189-94. PMID: 2536257.
        View in: PubMed
      144. Johnson RP, Schooley R. Update on antiretroviral agents other than zidovudine. AIDS. 1989; 3 Suppl 1:S145-51. PMID: 2482054.
        View in: PubMed
      145. Vogt MW, Durno AG, Chou TC, Coleman LA, Paradis TJ, Schooley R, Kaplan JC, Hirsch MS. Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. J Infect Dis. 1988 Aug; 158(2):378-85. PMID: 2841378.
        View in: PubMed
      146. de la Monte SM, Gabuzda DH, Ho DD, Brown RH, Hedley-Whyte ET, Schooley R, Hirsch MS, Bhan AK. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol. 1988 May; 23(5):485-92. PMID: 2839106.
        View in: PubMed
      147. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley R, Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988 Apr 1; 240(4848):64-6. PMID: 2451288.
        View in: PubMed
      148. Pomerantz RJ, Kuritzkes DR, de la Monte SM, Rota TR, Baker AS, Albert D, Bor DH, Feldman EL, Schooley R, Hirsch MS. Infection of the retina by human immunodeficiency virus type I. N Engl J Med. 1987 Dec 24; 317(26):1643-7. PMID: 3479685.
        View in: PubMed
      149. Pomerantz RJ, Schooley R. Therapy of human immunodeficiency virus infections. Clin Lab Med. 1987 Dec; 7(4):793-813. PMID: 2446817.
        View in: PubMed
      150. Blumberg RS, Paradis T, Hartshorn KL, Vogt M, Ho DD, Hirsch MS, Leban J, Sato VL, Schooley R. Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. J Infect Dis. 1987 Dec; 156(6):878-84. PMID: 3479500.
        View in: PubMed
      151. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley R. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23; 317(4):185-91. PMID: 3299089.
        View in: PubMed
      152. Ho DD, Sarngadharan MG, Hirsch MS, Schooley R, Rota TR, Kennedy RC, Chanh TC, Sato VL. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987 Jun; 61(6):2024-8. PMID: 2437327.
        View in: PubMed
      153. Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS, Schooley R. Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis. 1987 May; 155(5):877-90. PMID: 3031170.
        View in: PubMed
      154. Hartshorn KL, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley R, Hirsch MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987 Feb; 31(2):168-72. PMID: 3471180.
        View in: PubMed
      155. Schooley R, Blumberg RS, Vogt M, Hartshorn K, Hirsch MS. Therapeutic perspectives in human immunodeficiency virus infection. J Exp Pathol. 1987; 3(4):661-80. PMID: 3331652.
        View in: PubMed
      156. Hartshorn KL, Neumeyer D, Vogt MW, Schooley R, Hirsch MS. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses. 1987; 3(2):125-33. PMID: 3113463.
        View in: PubMed
      157. Vogt M, Schooley R, Hirsch MS. [Chemotherapy and immunoprophylaxis of HIV infection]. Schweiz Rundsch Med Prax. 1986 Nov 25; 75(48):1471-5. PMID: 2432642.
        View in: PubMed
      158. Hartshorn KL, Sandstrom EG, Neumeyer D, Paradis TJ, Chou TC, Schooley R, Hirsch MS. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother. 1986 Jul; 30(1):189-91. PMID: 3019235.
        View in: PubMed
      159. Felsenstein D, D'Amico DJ, Hirsch MS, Neumeyer DA, Cederberg DM, de Miranda P, Schooley R. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985 Sep; 103(3):377-80. PMID: 2992334.
        View in: PubMed
      160. Lind SE, Gross PL, Andiman WA, Stone GC, Schooley R, Harris NL. Malignant lymphoma presenting as Kaposi's sarcoma in a homosexual man with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Mar; 102(3):338-40. PMID: 2982306.
        View in: PubMed
      161. Garner JG, Colvin RB, Schooley R. A flow cytometric technique for quantitation of B-cell activation. J Immunol Methods. 1984 Feb 24; 67(1):37-51. PMID: 6321600.
        View in: PubMed
      162. Dolin R, Reichman RC, Roessner KD, Tralka TS, Schooley R, Gary W, Morens D. Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. J Infect Dis. 1982 Aug; 146(2):184-9. PMID: 6286787.
        View in: PubMed
      Robert's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _